Apolipoprotein E (ApoE) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Apolipoprotein E (ApoE) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Apolipoprotein E (ApoE) - Pipeline Review, H1 2016', provides in depth analysis on Apolipoprotein E (ApoE) targeted pipeline therapeutics. 

The report provides comprehensive information on the Apolipoprotein E (ApoE) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Apolipoprotein E (ApoE) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Apolipoprotein E (ApoE) 
- The report reviews Apolipoprotein E (ApoE) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Apolipoprotein E (ApoE) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Apolipoprotein E (ApoE) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Apolipoprotein E (ApoE) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Apolipoprotein E (ApoE) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Apolipoprotein E (ApoE) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Apolipoprotein E (ApoE) Overview 6
Therapeutics Development 7
Apolipoprotein E (ApoE) - Products under Development by Stage of Development 7
Apolipoprotein E (ApoE) - Products under Development by Therapy Area 8
Apolipoprotein E (ApoE) - Products under Development by Indication 9
Apolipoprotein E (ApoE) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Apolipoprotein E (ApoE) - Products under Development by Companies 12
Apolipoprotein E (ApoE) - Products under Development by Universities/Institutes 14
Apolipoprotein E (ApoE) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Apolipoprotein E (ApoE) - Companies Involved in Therapeutics Development 23
LipimetiX Development, Inc. 23
ReXceptor Inc. 24
Apolipoprotein E (ApoE) - Drug Profiles 25
AEM-28 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
AEM-2802 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
AEM-2814 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
bexarotene - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Monoclonal Antibodies to Target ApoE for Alzheimer's Disease - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Recombinant ApoE4 for Dyslipidemia - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecules to Activate ApoE for Alzheimer's Disease - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Apolipoprotein E (ApoE) - Featured News & Press Releases 34
Oct 14, 2015: Capstone Therapeutics Announces Allowance of U.S. Patent for Treatment of Diabetes With Apo E Mimetic Peptides 34
Jul 23, 2015: Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides 35
Dec 16, 2014: Capstone Therapeutics Announces Phase 1b/2a Study Results for AEM-28 Showing Safety and Biomarker Efficacy Signals 36
Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals 37
Jun 11, 2014: Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1b/2a Human Clinical Trial in Refractory Hypercholesterolemic Subjects 38
Jun 05, 2014: ApoE Immunotherapy and Prions Advance in Alzheimer's Research 38
Apr 08, 2014: Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1 Human Clinical Trial in LDL/non-HDL Cholesterol Reduction 39
Nov 19, 2013: Capstone Therapeutics Announces a LipimetiX Development Presentation at the American Heart Association Scientific Sessions: Pre-Clinical Data Demonstrating Significant Post Treatment Benefit of AEM-28 on Established Atherosclerotic Lesions 39
Apr 24, 2013: ADDF And BrightFocus Foundation Collaborate To Fund Phase I Study Of Cancer Drug Bexarotene In Alzheimer's Disease Patients 40
Dec 06, 2012: Capstone Therapeutics's Partner LipimetiX Obtains Orphan Drug Designation For AEM-28 To Treat Homozygous Familial Hypercholesterolemia 41
Feb 09, 2012: Case Western Reserve Researchers Discover FDA-approved Drug Rapidly Clears Amyloid From Brain And Reverses Cognitive Defects 41
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45

List of Tables

Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Stage and Mechanism of Action, H1 2016 18
Number of Products by Stage and Route of Administration, H1 2016 20
Number of Products by Stage and Molecule Type, H1 2016 22
Pipeline by LipimetiX Development, Inc., H1 2016 23
Pipeline by ReXceptor Inc., H1 2016 24